GERMANY - NOXXON Pharma raises EUR 37m

NOXXON Pharma AG, a developer of mirror image oligonucleotide therapeutics, has closed a EUR 37m series-C financing round. The main investors are TVM Capital, Sofinnova Partners and Edmond de Rothschild Investment Partners. Other investors contributing to this round are Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft, Seventure Partners, Dow Venture Capital, IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, VC Fonds Berlin GmbH. The new capital will be used to fund the pre-clinical and clinical development of the company’s lead products in kidney disease and ophthalmology.